5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.25▲ | 2.24▲ | 2.25▲ | 2.41▲ | 2.36▲ |
MA10 | 2.27▲ | 2.27▲ | 2.26▲ | 2.37▲ | 2.41▲ |
MA20 | 2.28▲ | 2.28▲ | 2.29▲ | 2.37▲ | 2.38▲ |
MA50 | 2.31▼ | 2.32▼ | 2.33▼ | 2.42▲ | N/A |
MA100 | 2.36▼ | 2.41▼ | 2.41▼ | 2.37▲ | N/A |
MA200 | 2.41▼ | 2.34▼ | 2.31▲ | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.001▲ | 0.001▲ | 0.001▲ | 0.016▲ | 0.111▲ |
RSI | 51.847▲ | 50.882▲ | 50.678▲ | 54.301▲ | 42.162▼ |
STOCH | 65.000 | 64.583 | 64.471 | 89.855▲ | 42.241 |
WILL %R | -13.043▲ | -13.043▲ | -13.043▲ | 0.000▲ | -57.649 |
CCI | 45.835 | 41.287 | 42.016 | 113.176▲ | -16.210 |
Thursday, July 31, 2025 04:48 AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ('BriaCell” or the 'Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, ...
|
Tuesday, July 29, 2025 04:59 PM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) , a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, has reported updated survival data from its ...
|
Friday, July 25, 2025 04:50 AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
08/08/25 | 2.38 | 2.4481 | 2.38 | 2.4481 | 657 |
07/08/25 | 2.43 | 2.43 | 2.43 | 2.43 | 500 |
06/08/25 | 2.43 | 2.43 | 2.43 | 2.43 | 0 |
05/08/25 | 2.29 | 2.43 | 2.29 | 2.43 | 484 |
04/08/25 | 2.33 | 2.33 | 2.32 | 2.32 | 363 |
01/08/25 | 2.415 | 2.42 | 2.075 | 2.31 | 6,700 |
31/07/25 | 2.30 | 2.42 | 2.29 | 2.42 | 1,600 |
30/07/25 | 2.32 | 2.35 | 2.211 | 2.26 | 1,900 |
29/07/25 | 2.32 | 2.32 | 2.30 | 2.30 | 1,200 |
28/07/25 | 2.21 | 2.33 | 2.14 | 2.32 | 7,054 |
|
|
||||
|
|
||||
|
|